IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

2016530 citationsJournal Articlebronze Open Access

Authors

These preclinical results indicate that targeted inhibition of IL-6 may enhance the efficacy of anti-PD-L1 in PDAC.

Good health and well-being

Published in: Gut

Volume 67, Issue 2, pp. 320-332

Field-Weighted Citation Impact: 15.77